Prasad S. Adusumilli, MD, FACS, discusses the potential role of chimeric antigen receptor T-cell therapy as treatment of solid tumors now that they have demonstrated safety and efficacy in some Hematologic Malignancies.
In an interview with Targeted Oncology, David G. Maloney, MD, PhD, discussed findings from administration of chimeric antigen receptor T-cell therapy in the outpatient setting for patients with B-cell lymphomas.
Although many of the patients in the study had heavy tumor burden, were in poor physical condition, or had highly aggressive characteristics, they were still able to achieve a satisfactory overall response rate and complete response rate with the tandem CD19/CD20 CAR-engineered T-cell therapy.
In an interview with Targeted Oncology, Andrea Price, APN, discussed the importance of integrating the electronic medical record team into the clinical care team for the treatment of patients with cancer receiving CAR T-cell therapy.
The review of the Biologics License Application for idecabtagene vicleucel has been put on hold. The FDA issued a Refusal to File letter due to the need for additional data from the developer of the drug.
Relevant professional meetings and oncology publications exploded with research and news about chimeric antigen receptor T cells, and this cellular therapy strategy is now being explored across hematologic and solid malignancies.
Patients with relapsed or refractory chronic lymphocytic leukemia who received a higher dose of CAR T cells, achieved complete responses, regardless of cell dose, which was highly correlated with long-term survival.